{ }
Very Negative
Negative
Neutral
Positive
Very Positive
2025-03-292025-03-292025-03-302025-03-302025-03-312025-03-312025-04-012025-04-012025-04-022025-04-022025-04-032025-04-032025-04-042025-04-0425243035239551697934133110129115964826494281103655419400400320320240240160160808000
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-03-292025-03-292025-03-302025-03-302025-03-312025-03-312025-04-012025-04-012025-04-022025-04-022025-04-032025-04-032025-04-042025-04-0437294942614035216969725613812117613298925337362323400400320320240240160160808000
Download SVG
Download PNG
Download CSV

Poseida Therapeutics acquisition by Roche receives US regulatory approval

Poseida Therapeutics has announced that the US waiting period for its $1.5 billion acquisition by Roche has expired, as confirmed in a filing with the US Securities and Exchange Commission. This marks a significant step forward in the deal's progression.

Roche secures US approval for Poseida Therapeutics acquisition worth 1.5 billion

Roche has received approval from US antitrust authorities for its $1.5 billion acquisition of Poseida Therapeutics. This clearance marks a significant step in Roche's expansion within the biotech sector, enhancing its portfolio and capabilities in innovative therapies.

digital realty trust upgraded to buy with increased price target by analysts

Digital Realty Trust (NYSE:DLR) has been upgraded to a "buy" rating by UBS Group, raising its target price from $147 to $205, indicating a potential upside of 14.28%. Analysts have generally positive views, with a consensus rating of "Moderate Buy" and an average price target of $174.74. The company reported a quarterly EPS of $0.09, missing expectations, while revenue was in line with forecasts at $1.43 billion.

bank of america sees institutional investment growth and analyst upgrades

Insiders hold 0.29% of Bank of America's stock, while institutional investors own 70.71%. Recent upgrades from UBS and Citigroup have raised the stock's price targets, with a consensus rating of "Moderate Buy" and an average target price of $46.97. The company reported $0.81 EPS for the last quarter, exceeding estimates, and has a market cap of $348.27 billion. Major shareholder Berkshire Hathaway sold over 4 million shares, reducing its stake slightly.

Ripple enhances RLUSD stablecoin's DeFi integration with Chainlink services

Ripple is enhancing the utility of its RLUSD stablecoin in decentralized finance (DeFi) by integrating Chainlink's data services. This integration, now live on the Ethereum blockchain, allows developers to utilize RLUSD for various DeFi activities, supporting secure and low-cost cross-border payments. With a market cap of $72 million, RLUSD aims to provide reliable pricing data essential for DeFi protocols, ensuring transparency and reliability in financial operations.

ripple enhances rlusd stablecoin integration with chainlink for decentralized finance

Ripple is enhancing the utility of its RLUSD stablecoin in decentralized finance (DeFi) by integrating Chainlink's services, which went live on the Ethereum blockchain. This integration allows developers to utilize RLUSD for trading, lending, and other DeFi activities, aiming to boost its adoption and appeal for secure, low-cost cross-border payments.With a market capitalization of $72 million, RLUSD is designed to provide reliable pricing data essential for DeFi applications, ensuring transparency and reliability in financial operations. Jack McDonald from Ripple emphasized that this collaboration positions RLUSD to support a wide range of use cases in decentralized financial systems.

ubs group initiates coverage on tyra biosciences with buy rating and price target

Ally Bridge Group NY LLC and Ensign Peak Advisors Inc. made significant new investments in Tyra Biosciences, with stakes worth approximately $4.23 million and $3.05 million, respectively. American Century Companies Inc. increased its stake by 582.9%, now holding 170,283 shares valued at $2.72 million. The company, focused on precision medicines for FGFR biology, has a consensus "Buy" rating from analysts, with a target price averaging $30.50, despite recent earnings missing expectations.

Cardano founder criticizes Trump's sentencing as divisive and politically motivated

Cardano founder Charles Hoskinson criticized the timing of Donald Trump's sentencing in the Manhattan hush-money case, calling it a divisive tactic that threatens a peaceful transition of power. He highlighted perceived inconsistencies in the U.S. justice system, citing Hunter Biden's recent pardon as evidence of unequal treatment. Hoskinson's comments reflect concerns that the ruling could exacerbate political polarization and distract from pressing national issues as Trump prepares to lead the country.

stock market update nvidia hits high uber partners with nvidia tencent falls

U.S. stock futures are little changed following a mixed session, with Nasdaq futures dipping slightly. Nvidia shares hit an all-time high after strong AI demand and CEO remarks, while Uber's stock rose on a collaboration with Nvidia for autonomous driving technology. Inari Medical soared 30% after being acquired by Stryker for $4.9 billion, while Tencent's stock fell 7% after being added to the Pentagon's "Chinese military companies" blacklist.

stock market update nvidia hits record high amid job data anticipation

Intuitive Surgical saw a 0.3% premarket rise, while Tesla's stock dipped 1.7% after a recent surge. Nvidia reached record highs following new AI initiatives unveiled at CES 2025, contributing to a positive trend in the Dow Jones and other major indexes ahead of key employment data. Apple's stock faced a downgrade, impacting its performance, while Microsoft and Amazon also showed slight gains. Notable stocks near buy points include BlackRock, Disney, TSMC, and Fortinet, as the market anticipates the Labor Department's job openings report.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.